<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03718559</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCVEP2018-01</org_study_id>
    <nct_id>NCT03718559</nct_id>
  </id_info>
  <brief_title>Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease</brief_title>
  <acronym>EPIC-CAD</acronym>
  <official_title>A Multi-centre, Open-labelled, Randomized Controlled Trial Comparing Two Different Anticoagulation Strategies in High-risk Atrial Fibrillation and Stable Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gi-Byoung Nam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety of Edoxaban with the combination of edoxaban and
      antiplatelet in patients with stable CAD (coronary artery stenosis ≥50% on medical treatment
      or revascularized stable CAD [≥ 12 months for acute coronary syndrome and ≥ 6 months after
      stable CAD]) and high-risk atrial fibrillation (CHA2DS2-VASc score ≥2).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2019</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of net Clinical Outcome</measure>
    <time_frame>1 year</time_frame>
    <description>composites of death, stroke, systemic embolic event, myocardial infarction, unplanned revascularization of a major coronary artery, major bleeding, and clinically relevant non-major bleeding event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of all cause death</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cardiovascular death</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of myocardial infarction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ischemic stroke</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of systemic embolism</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of unplanned revascularization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of composite of hard outcomes</measure>
    <time_frame>1 year</time_frame>
    <description>all cause death, myocardial infarction, ischemic stroke, and systemic embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of stent thrombosis</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of composite of Major or clinically relevant non-major bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>Major bleeding
Fatal bleeding
Bleeding in the critical site (Intracranial, retroperitoneal, intraocular, intraspinal, intra-articular, pericardial, intramuscular with compartment syndrome)
Bleeding causing a fall in haemoglobin level of 2g/dL or leading to transfusion of two or more units of whole blood or red cells.
Clinically relevant non-major bleeding
Requires or prolongs hospitalization
Requires lab evaluation
Requires imaging studies
Requires nasal packing or compression
Requires a therapeutic procedure
Requires interruption of study medication
Requires a change in concomitant therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of fatal bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>International Society on Thrombosis and Haemostasis(ISTH), The Bleeding Academic Research Consortium (BARC)5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of major bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>ISTH, BARC 3, The Thrombolysis in Myocardial Infarction (TIMI) major bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of minor bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>ISTH, BARC and TIMI criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of intracranial hemorrhage</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of gastrointestinal hemorrhage</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1028</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Stable Angina</condition>
  <condition>Stable Chronic Angina</condition>
  <arm_group>
    <arm_group_label>Edoxaban alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination of edoxaban plus single antiplatelet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>Taking edoxaban (Lixiana™, Daiichi-Sankyo Inc.) 60mg once daily. The dose of edoxaban will be reduced to 30mg once daily in patients with estimated creatinine clearance 15≤CrCL≤50mL/min by Cockcroft-Gault equation or weight is ≤60kg.</description>
    <arm_group_label>Combination of edoxaban plus single antiplatelet</arm_group_label>
    <arm_group_label>Edoxaban alone</arm_group_label>
    <other_name>Lixiana™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single Antiplatelet Agents</intervention_name>
    <description>Type of antiplatelet agent is dependant upon the investigator's discretion, but aspirin 100mg once daily is recommended.</description>
    <arm_group_label>Combination of edoxaban plus single antiplatelet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. A subject was ≥ 19 years of age

          2. Patients with nonvalvular atrial fibrillation with high embolic risk (CHA2DS2-VASc
             score ≥2)

          3. Patients with Stable coronary artery disease

               -  Coronary artery angiography or Coronary Computed Tomography Angiography confirmed
                  coronary artery disease (≥50 % stenosis of a major coronary artery) on medical
                  treatment. In case there is clinically significant moderate or more stenosis
                  however the percentage of stenosis on CAG or CCTA is not shown, it will be at the
                  investigator's discretion.

               -  Revascularized coronary artery disease (either Percutaneous Coronary Intervention
                  or coronary bypass surgery) whom the last revascularization should be performed
                  ≥12 months before study enrollment for the acute coronary syndrome and ≥6 months
                  for stable angina pectoris.

        Exclusion Criteria

          1. Patients with thrombocytopenia (platelet count &lt;100,000/ul)

          2. High risk of bleeding which prohibits the anticoagulant use. (baseline comorbidities,
             hyper or hypercoagulable state, increased prothrombin time or activated partial
             thromboplastin time)

          3. Prior history of intracranial haemorrhage or haemorrhage on Magnetic Resonance Imaging
             (MRI) or Computed Tomography (CT) imaging test

          4. Mechanical prosthetic valve or moderate to severe mitral stenosis

          5. The risk of bleeding increased due to the following reasons; i. history of
             gastrointestinal ulcers within 1 month ii. Malignant tumor with high risk of bleeding
             iii. Brain or spinal cord injury within 1 month iv. History of intracranial or
             intracerebral hemorrhage within 12 months v. Esophageal varices vi. Arteriovenous
             malformation vii. Vascular aneurysms viii. Spinal cord vascular abnormalities or
             intracerebral vascular abnormalities ix. Active bleeding x. Hemoglobin level &lt;7.0 g/dL
             or platelet count ≤ 50,000 / mm3 xi. History of major surgery within 1 month

          6. Uncontrolled severe hypertension

          7. Hemodynamically Unstable or pulmonary embolism requiring thrombolysis or pulmonary
             embolectomy

          8. History of hypersensitivity to Edoxaban or clopidogrel

          9. Genetic problem with galactose intolerance, Lapp lactase deficiency or
             glucose-galactose malabsorption

         10. Planned Percutaneous Coronary Intervention or coronary bypass surgery was planned
             within 1 year after randomization

         11. Liver cirrhosis or liver dysfunction (AST or ALT &gt; x3 of normal range or coagulation
             abnormality)

         12. Estimated CrCl by Cockcroft-Gault equation&lt;15 mL/min

         13. Life expectancy less than 12 months

         14. The subject was unable to provide written informed consent or participate in long-term
             follow-up

         15. Pregnant and/or lactating women

         16. Patients who are actively participating in another drug or device investigational
             study, which have not completed the primary endpoint follow-up period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duk-woo Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jung-hee Ham, PL</last_name>
    <phone>82230104728</phone>
    <email>cvcrc5@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hallym University Medical Center</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kyung-ha Park, MD</last_name>
      <email>pkhmd@naver.com</email>
    </contact>
    <investigator>
      <last_name>Kyung-ha Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Bucheon</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyung-oh Choi, MD</last_name>
      <email>mrgud@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Hyung-oh Choi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong-min Hwang, MD</last_name>
      <email>hwangjongmin00@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jong-min Hwang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dongguk University Ilsan Hospital</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong-rak Cho, MD</last_name>
      <email>nephrone@dau.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Yong-rak Cho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ki-hoon Kim, MD</last_name>
      <email>iron9411@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ki-hoon Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji-hyun Lee, MD</last_name>
      <email>89family@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Ji-hyun Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gi-byoung Nam, MD</last_name>
      <phone>+82230103159</phone>
      <email>gbnam@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Gi-byoung Nam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jong-young Lee, MD</last_name>
      <email>jyleeheart@naver.com</email>
    </contact>
    <investigator>
      <last_name>Jong-young Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kangdong KyungHee University hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun-sun Jin, MD</last_name>
      <email>eunsun.marcella@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eun-sun Jin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chang-hee Kwon, MD</last_name>
      <email>vertex_77@naver.com</email>
    </contact>
    <investigator>
      <last_name>Chang-hee Kwon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eui-geun Choi, MD</last_name>
      <email>choiek417@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eui-geun Choi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic Univ. of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>VHS medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-kyung Hwang, MD</last_name>
      <email>dangtong@naver.com</email>
    </contact>
    <investigator>
      <last_name>Jin-kyung Hwang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bo-young Jeong, MD</last_name>
      <email>CBY6908@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Bo-young Jeong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, St. Vincent's Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yu-mi Hwang, MD</last_name>
      <email>youmi0607@naver.com</email>
    </contact>
    <investigator>
      <last_name>Ki-dong Yoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-mi Hwang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulsan Univeristy Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyung-min Park, MD</last_name>
      <email>min8684@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Kyung-min Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki-won Hwang, MD</last_name>
      <email>korea.hwang@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ki-won Hwang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Gi-Byoung Nam</investigator_full_name>
    <investigator_title>Professor, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea</investigator_title>
  </responsible_party>
  <keyword>Edoxaban</keyword>
  <keyword>antiplatelet</keyword>
  <keyword>anticoagulant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

